Anatara Lifesciences Ltd (ASX:ANR) Q3 FY21 Activities Report
Q3 FY21 Activities ReportMelbourne, April 27, 2021 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR), a developer of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 31 March 2021, along with the Company s Appendix 4C cash flow report.
Commenting on the quarter, CEO Steve Lydeamore said, Anatara is pleased to have successfully progressed two key milestones during the period - a successful trial for Anatara s proprietary enriched formulation for poultry in water, and ethics approval to start the human IBS trial. Anatara now has approval to commence two separate human trials for its Gastrointestinal Re-Programming complementary medicine (GaRP), and there appears to be a wider appreciation of the Company s human health initiatives and the potential to improve overall human wellbeing with a market different